Edition:
United States

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

35.46USD
17 Feb 2017
Change (% chg)

$0.02 (+0.06%)
Prev Close
$35.44
Open
$35.22
Day's High
$35.46
Day's Low
$35.19
Volume
372,796
Avg. Vol
703,108
52-wk High
$57.81
52-wk Low
$30.90

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company's business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1),... (more)

Overall

Beta: 0.71
Market Cap(Mil.): $70,946.85
Shares Outstanding(Mil.): 2,012.56
Dividend: 0.66
Yield (%): 3.74

Financials

  NVO.N Industry Sector
P/E (TTM): 16.51 28.47 29.39
EPS (TTM): 2.14 -- --
ROI: 75.08 13.57 13.06
ROE: 82.23 14.45 14.19

European shares fall weighed down by poor earnings; Reckitt up

* Novo Nordisk, Deutsche Bank among top losers after poor results

Feb 02 2017

Drugmaker Novo Nordisk cautious over unpredictable U.S. politics

COPENHAGEN Novo Nordisk shares took another hit on Thursday as the world's top maker of diabetes drugs disappointed investors with a lower 2017 sales and profit growth forecast due to price pressure and U.S. political uncertainty.

Feb 02 2017

UPDATE 2-Drugmaker Novo Nordisk cautious over unpredictable U.S. politics

COPENHAGEN, Feb 2 Novo Nordisk shares took another hit on Thursday as the world's top maker of diabetes drugs disappointed investors with a lower 2017 sales and profit growth forecast due to price pressure and U.S. political uncertainty.

Feb 02 2017

European shares edge lower on disappointing company updates

LONDON, Feb 2 European shares fell on Thursday after disappointing company updates, with Denmark's Novo Nordisk leading the market down and Finnish retailer Kesko weakening on lower-than-expected sales.

Feb 02 2017

BRIEF-Novo Nordisk CEO: We are not concerned about Trump

Feb 2 Drugmaker Novo Nordisk CEO Lars Fruergaard Jorgensen made the following comments during a call with journalists:

Feb 02 2017

Drugmaker Novo Nordisk lowers 2017 sales, profit outlook

COPENHAGEN, Feb 2 Denmark's Novo Nordisk , the world's top maker of diabetes drugs, said fourth-quarter operating profit came in a touch below forecasts and lowered its 2017 operating profit and sales growth outlook measured in local currency terms.

Feb 02 2017

BRIEF-Novo Nordisk cuts 2017 sales, profit outlook in local currencies

* Says 2017 sales growth is expected to be in the range of a decline of 1 percent to a growth of 4 percent measured in local currencies

Feb 02 2017

Stock futures signal slightly higher market open. For more see the European equities LiveMarkets blog

LONDON, Jan 31 Live coverage of European markets now available on cpurl://apps.cp./cms/?pageId=livemarkets

Jan 31 2017

Sanofi, Novo Nordisk and Lilly named in patients' price fixing suit

NEW YORK Three of the biggest makers of diabetes treatments, Sanofi SA, Novo Nordisk and Eli Lilly and Co, were named in a class action lawsuit about price fixing filed by a group of patients.

Jan 30 2017

Sanofi, Novo Nordisk and Lilly named in patients' price fixing suit

NEW YORK, Jan 30 Three of the biggest makers of diabetes treatments, Sanofi SA, Novo Nordisk and Eli Lilly & Co, were named in a class action lawsuit about price fixing filed by a group of patients.

Jan 30 2017

More From Around the Web

Competitors

  Price Chg
Sanofi SA (SASY.PA) €81.49 --
Eli Lilly and Co (LLY.N) $80.39 +0.35

Earnings vs. Estimates